A Study Assessing Varenicline (Chantix) to Treat Tobacco Dependence in Breast Cancer Patients Scheduled for Mastectomy and Reconstructive Surgery

Protocol
11-136
Full Title
Treatment of Tobacco Dependence in Breast Cancer Patients: A Randomized Trial of Varenicline (Chantix)
Phase
III
Purpose

Breast cancer patients who smoke are at risk for more complications after surgery (such as delayed wound healing and infections) than nonsmokers. This study is assessing two approaches to help breast cancer patients stop smoking before mastectomy and breast reconstruction surgery.

Patients will be randomly assigned to one of two groups. One group will receive the smoking cessation drug varenicline (marketed as Chantix), and the other will receive a placebo. Both groups will also receive smoking cessation counseling. Researchers hope the results of this study will help improve smoking cessation treatment for breast cancer patients scheduled for surgery.

Eligibility

This study will include breast cancer patients (age 18 and older) who are scheduled to have mastectomy and reconstructive surgery at Memorial Sloan-Kettering Cancer Center two or more weeks later and who have been advised to stop smoking before surgery. Women must have smoked 10 or more cigarettes a day in the past year and at least one pack of cigarettes within the seven days prior to entering the study.

For more information about this study, please contact Dr. Jamie Ostroff at 646-888-0041.

Disease(s)
Breast Cancer
Tobacco Cessation
Locations
Related Diseases